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Abstract - The aim of this study was to examine the effects of intrastriatally injected nitric oxide synthase (NOS) inhibitors, 
Nω-nitro-l-arginine methyl ester (L-NAME) and 7-nitroindazole (7-NI), on quinolinic acid (QA)-induced toxicity in se-
lective vulnerable brain regions of adult Wistar rats. QA was administered into the striatum unilaterally, in a single dose of 
150 nM/L with a stereotaxic instrument. The other two experimental groups were pretreated with L-NAME and 7-NI, re-
spectively. The control group of animals was treated with 0.154 mM/L saline solution. The animals were decapitated seven 
days after the treatment. Samples of both striatum and forebrain cortex were prepared for measurement of acetylcholin-
esterase (AChE) activity. QA injection revealed a significant increase in AChE activity in both the ipsi- and contralateral 
striatum and forebrain cortex compared to the control animals. Treatment with NOS inhibitors, followed by QA, very 
clearly demonstrated lower levels of AChE bilaterally in these brain structures, compared to the QA-treated group. 
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INTRODUCTION
Huntington’s disease (HD) is an autosomal domi-
nant neurodegenerative disorder marked by selec-
tive striatal degeneration, motor dysfunction and 
cognitive deterioration with learning impairment, 
memory loss and dementia (Beister et al., 2004). 
Cognitive decline consists of spatial learning defi-
cits,  working  memory  and  retrieval  dysfunction 
and perseverative behavior. Our studies have indi-
cated that acute intrastriatal injections of the en-
dogenous N-methyl-D-aspartate (NMDA) receptor 
agonist, quinolinic acid (QA), can mimic some of 
the neuroanatomical and behavioral deficits of HD 
(Maksimović et al., 2002). Intrastriatal injections of 
QA have been shown to produce an HD-like pat-
tern of neurodegeneration, including loss of striatal 
projection neurons (Armstrong et al., 2000). The 
disease causes widespread loss of cells from the cor-
pus striatum, which causes the motor disturbance 
(Watts and Dunnett, 1998).
HD  is  characterized  by  the  loss  of  neurons  in 
the basal forebrain cholinergic cells that project to 
the cerebral cortex and hippocampus (Smith et al., 
2006). These impairments have been correlated with 
the memory loss noted in the dementia of HD. This 
“cholinergic hypothesis” has led to the rational design 
of drugs to enhance or stimulate acetylcholine (ACh)-
mediated neurotransmission (Walker et al., 2011). 
The nitric oxide (NO) synthase (NOS) inhibitors 
L-NAME  (Nω-nitro-l-arginine  methyl  ester)  and 
7-NI (7-nitroindazole) are widely used to study the 
role of NO in physiological and pathological process 
(Boje, 2004). The aim of this study was to examine 
the effects of intrastriatally injected L-NAME and 
7-NI on QA-induced striatal toxicity, as well as the 
role of ACh in the pathogenesis in the QA-induced 
model of HD.520 I. STEVANOVIĆ ET AL.
MATERIALS AND METHODS
Animals
The experimental animals were treated according to 
the Guidelines for Animal Study, No. 282-12/2002 
(Ethics Committee of the Military Medical Academy, 
Belgrade). 
The  experiments  were  performed  on  adult 
Wistar  rats,  weighing  between  200-250  g,  ran-
domly divided into one control group (n = 10) and 
three experimental groups (n = 9, each). Animals 
were housed (five rats per cage) under standard-
ized housing conditions (ambient temperature of 
23±2°C, relative humidity 55±3% and a light/dark 
cycle  of  13  and  11  h,  respectively)  and  had  free 
access to standard laboratory pellet food and tap 
water.  All  the  experiments  were  performed  after 
a 7-day period of adaptation to laboratory condi-
tions, and were carried out between 9 a.m. and 1 
p.m. Experimental protocols were approved by the 
Local Animal Care Committee and conformed to 
the recommendations given in “Guide for the Care 
and Use of laboratory Animals” (National Academy 
Press, Washington, D.C., 1996). 
Experimental procedure
Before treatment, the Wistar rats were intraperito-
neally (i.p.) anesthetized with pentobarbital-Na in 
doses of 40.5 mg/kg body weight. QA was adminis-
tered into the striatum of adult Wistar rats, unilater-
ally in a single dose of 150 nM/L using a Hamilton 
syringe, with a stereotaxic instrument for small labo-
ratory animals (coordinates: 8.4 A; 2.6 L and 4.8 V) 
(Paxinos and Watson, 1986). The second and third 
experimental groups were treated with L-NAME and 
QA (L-NAME in a dose of 1 x 10-4 g) and 7-NI and 
QA (7-NI in a dose of 1 x 10-4 g). 7-NI was applied 
immediately before the neurotoxin, in contrast to L-
NAME, which was given thirty minutes before QA. 
The control group of animals was treated with 0.154 
mM/L  saline  solution  likewise.  A  liquid  overload 
(amounts greater than 10 µL) could provoke a brain 
tissue edema (Fukushima et al., 1994). 
The brain tissue preparation
The animals were decapitated seven days after the 
treatment and the heads were frozen immediately 
(-70°C). The brain structures – striatum and fore-
brain  cortex,  were  dissected  on  ice,  and  each  tis-
sue slice (approximately 0.1 g) was transferred into 
a tube of 1 ml cold, buffered sucrose medium (0.25 
M/L sucrose with 0.1 mM/L EDTA in 50 mM K-Na 
phosphate buffer, pH 7.2). Homogenization of the 
tissue in the sucrose medium was performed by a 
homogenizer (Tehtnica, Zelezniki, Slovenia) at 800 
rotation/min on ice. The homogenates were centri-
fuged at 1000 x g, for 15 min at 4°C. The precipitates 
were redispersed in sucrose medium and centrifuged 
again. The supernatants were centrifuged at 2500 x 
g for 30 min at 4°C and the obtained precipitates 
were redispersed in 1.5 mL of deionized water. The 
samples were centrifuged at 2000 x g for 15 min at 
4°C and the supernatants (crude mitochondrial frac-
tions) were stored at -70°C (Gurd et al., 1974). Total 
protein concentration was estimated with bovine se-
rum albumin as a standard (Lowry et al., 1951). 
Biochemical analyses
Acetylcholine esterase (AChE) activity was measured 
in the ipsi- and contralateral striatum and forebrain 
cortex. The method is based on the ability of AChE 
to degrade acethyltiocholine iodide into the prod-
uct that binds DTNB (5,5-dithiobis-2-nitrobenzoev 
acid), thus forming a yellow color compound. The 
change in absorbance was followed in 3-5 min inter-
vals at 412 nm (Micic and Petronijevic, 2000). The 
results were expressed as µM acethyltiocholine per 
g proteins.
Reagents
All  used  chemicals  were  of  analytical  grade.  The 
following compounds were used in this study: qui-
nolinic acid (QA), Nω-nitro-l-arginine methyl ester 
(L-NAME), 7-nitroindazole (7-NI) and acethyltio-
choline  iodide,  and  were  purchased  from  Sigma-
Aldrich (Sr. Louis, USA). 5,5-dithiobis-2-nitroben-
zoev  acid  (DTNB)  was  purchased  from  Merck QUINOLINIC ACID INTOxICATION IN THE RAT BRAIN 521
(Darmstadt, Germany). All drug solutions were pre-
pared on the day of the experiment.
Statistical analysis
The program STATISTICA 5.0 was used to perform 
one-way ANOVAs and post hoc Turkey tests (0.05 
confidence value).
RESULTS
The obtained results of biochemical analysis showed 
that AChE activity was significantly elevated in the 
ipsi- (p <0.01) and contralateral (p <0.01) striatum 
of QA-injected animals in comparison with control 
groups (Fig. 1). The treatment with L-NAME fol-
lowed by QA significantly decreased AChE activity 
in the contralateral striatum compared to the QA 
group (p <0.01). In addition, the activity of AChE 
significantly  decreased  bilaterally  in  the  forebrain 
cortex in the 7-NI+QA group compared to the QA-
injected animals (Fig. 1).
The  AChE  activity  obtained  in  the  forebrain 
cortex (Fig, 2) was similar: significantly increased 
activity of AChE in both the ipsi- (p <0.001) and 
contralateral  (p  <0.01)  forebrain  cortex  compared 
to controls, and decreased AChE activity in both the 
L-NAME+QA (p <0.05) and 7-NI+QA (p  <0.01 in 
ipsilateral and p <0.05 in contralateral forebrain cor-
tex) in comparison with the QA group (Fig. 2).
DISCUSSION
The bilateral increase in AChE activity in both the 
striatum and forebrain cortex seven days after QA 
application suggests a direct involvement of this neu-
rotoxin in the modulation of enzyme activity. NOS 
Fig. 1. The AChE activity (µM acethyltiocholine/g proteins) in the ipsi- and contralateral striatum. CG – control group animals treated 
with saline solution in dose 0.154 mM/L, QA – quinolinic acid in dose 150 nM/L (for HD induction protocol see Section Animals and 
Methods), L-NAME+QA – L-NAME in dose of 1 x 10-4 g was given 30 min before QA, 7-NI+QA – 7-NI in dose of 1 x 10-4 g was given 
just before the neurotoxin. Bars on the graph represent mean ± SEM from 9-10 animals for each group. Labels of statistical significance: 
c – compared to control group; q – compared to QA group. Statistical significance was considered at: *p <0.05 (L-NAME+QA vs CG, 
7-NI+QA vs CG and 7-NI+QA vs QA in ipsilateral striatum, 7-NI+QA vs CG in contralateral striatum), **p  0.01 (QA vs CG in ipsilat-
eral striatum, QA vs CG, L-NAME+QA vs CG, L-NAME+QA vs QA and 7-NI+QA vs QA in contralateral striatum), one-way ANOVA, 
Turkey test.522 I. STEVANOVIĆ ET AL.
inhibitors  (L-NAME  and  7-NI,  respectively)  with 
neurotoxin lead to reduced AChE activity bilaterally 
in both the striatum and forebrain cortex.
Endogenous ACh exerts a complex modulation 
of striatal synaptic transmission, which produces 
both short-term and long-term effects. ACh-medi-
ated mechanisms might be of crucial importance in 
processing the cortical input to the striatum. Stri-
atal  neurons  receive  a  myriad  of  synaptic  inputs 
originating from different sources. Massive affer-
ents from all areas of the cortex represent the most 
important source of excitatory amino acids, where-
as the nigrostriatal pathway and intrinsic circuits 
provide the striatum with dopamine, ACh, GABA, 
NO and adenosine (Perluigi et al., 2005). All these 
neurotransmitter systems interact with each other 
and with voltage-dependent conductances to regu-
late the efficacy of the synaptic transmission within 
this nucleus. The integrative action exerted by stri-
atal projection neurons on this converging informa-
tion dictates the final output of the striatum to the 
other basal ganglia structures (Bonelli et al., 2004). 
During  pathological  conditions,  striatal  synaptic 
transmission is altered, depending on the presyn-
aptic inhibition of transmitter release and opposite 
membrane  potential  changes  that  occur  in  pro-
jection  neurons  and  in  cholinergic  interneurons. 
These ionic mechanisms might partially explain the 
selective neuronal vulnerability observed both in 
the striatum and forebrain cortex during HD (Nop-
oulos et al., 2010). 
Fig. 2. The AChE activity (µM acethyltiocholine/g proteins) in the ipsi- and contralateral forebrain cortex. CG – control group ani-
mals treated with saline solution in dose 0.154 mM/L, QA – quinolinic acid in dose 150 nM/L (for HD induction protocol see Section 
Animals and Methods), L-NAME+QA – L-NAME in dose of 1 x 10-4 g was given 30 min before QA, 7-NI+QA – 7-NI in dose of 1 
x 10-4 g was given just before the neurotoxin. Bars in the graph represent mean ± SEM from 9-10 animals for each group. Labels of 
statistical significance: c – compared to control group; q – compared to QA group. Statistical significance was considered at: *p <0.05 
(L-NAME+QA vs QA in ipsilateral forebrain cortex, L-NAME+QA vs QA and 7-NI+QA vs QA in contralateral forebrain cortex), **p 
<0.01 (7-NI+QA vs QA in ipsilateral forebrain cortex, QA vs CG, 7-NI+QA vs CG in contralateral forebrain cortex), ***p <0.001 (QA vs 
CG and L-NAME+QA vs CG in ipsilateral forebrain cortex, L-NAME+QA vs CG in contralateral forebrain cortex) one-way ANOVA, 
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Intrastriatal application of QA, an endogenous 
NMDA agonist, bilaterally in the striatum resulted 
in increased AChE activity, a biochemical marker for 
cholinergic neurons (Fig. 1). Studies have shown that 
QA interacts with a subgroup of NMDA receptors 
and when directly injected into brain areas, it de-
stroys most neuronal cells bodies sparing fibers and 
neuronal terminals (Kalonia et al., 2012). However, 
other studies have shown that cells in the nucleus 
basalis remain intact in HB, as well as cholinacetyl 
transferase activity. Also, cortical NMDA receptors 
are more sensitive to QA than those located in the 
cerebellum or the spinal cord, which suggests the 
existence  of  multiple  forms  of  NMDA  receptors 
can probably be explained by considering that QA 
is a relatively poor agonist for the NMDA receptor 
complex containing either NR2C or NR2D subunits, 
while it interacts with a relatively high affinity with 
the NMDA receptor complex containing NR2B sub-
units (Zeron et al., 2004). Our study also showed an 
increase in AChE activity bilaterally in the forebrain 
cortex after administration of QA (Fig. 2). A possi-
ble explanation for the increased AChE activity after 
QA injection may be that in neurons with increased 
release of ACh, its synthesis is increased from mem-
brane choline phospholipids. Phospholipids are de-
graded, as the plasma membrane, whose properties 
change, leading to the formation of free radicals in 
the form of lipid peroxides (Zou et al., 1999; Samuel 
et al., 2000).
To assess the intermediary role of NO in the neu-
rotoxicity elicited by this toxin, its action was tested 
in  animals  treated  with  L-NAME  and  7-NI.  De-
creased AChE activity after L-NAME+QA adminis-
tration contralaterally in the striatum and bilaterally 
in the forebrain cortex, compared to the QA group, 
is probably due to the reduced release of ACh, which 
is a substrate of the enzyme (Fig. 1, 2). On the other 
hand, a selective inhibitor of neuronal NOS (7-NI) 
with QA decreased the activity of AChE bilaterally in 
both brain structures; this is probably due to reduced 
ACh release (Figs. 1, 2). One of the most prominent 
cholinergic losses after the application of NOS in-
hibitors is the reduced number of nicotinic ACh re-
ceptors in the hippocampus and cortex (Buonomano 
and Merzenck, 1998). This deficit results in reduced 
nicotinic cholinergic excitation, which may impair 
not only postsynaptic depolarization but also presy-
naptic neurotransmitter release and Ca2+-dependent 
intracellular signaling, including transcriptional ac-
tivity (Foskett, 2010). 
In  conclusion,  our  results  indicated  that  NO-
mediated neurotoxicity spread temporally and spa-
tially in the forebrain cortex after intrastriatal QA 
application  with  changes  of  cholinergic  transmis-
sion. NOS inhibitors, like both L-NAME and 7-NI 
could protect the cells in the striatum and forebrain 
cortex from QA-induced damage and may therefore 
limit the retrograde and anterograde spread of neu-
rotoxicity.
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